Dishman’s Study Says Vitamin D Deficiency In COVID-19 Patients
DISHMAN CARBOGEN AMCIS LTD announces positive results from a clinical research study conducted in collaboration with Boston University School of Medicine, revealing a positive response in vitamin D deficiency/insufficiency in patients with covid-19.
Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, appreciates the study results of a new Clinical Data Analysis, which show that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in COVID-19 patients and improved immune function by increasing blood lymphocyte percentages. Tehran University of Medical Sciences and Boston University School of Medicine supervised the research, which was funded by a grant from Dishman Carbogen Amcis Ltd wholly owned subsidiary CARBOGEN AMCIS B.V.
With over 70 years of experience in the industry, Dishman Carbogen Amcis Ltd (DCAL) is a leading global manufacturer of vitamin D, its analogues, and related APIs. DCAL partnered with Dr. Michael Holick, MD, PhD, professor of medicine, physiology and biophysics, and molecular medicine at Boston University School of Medicine, and his team for the Clinical Research Study on 25-Hydroxyvitamin D3 (Calcifediol) treatment of COVID-19 hospitalised patients to be conducted by the Tehran University of Medical Sciences.
“A person’s vitamin D status is defined as the person’s blood level of the vitamin’s 25-hydroxy metabolite (Calcifediol), i.e. the vitamin’s natural form in circulation which the body can quickly access and finally activate. Therefore, Dishman Carbogen Amcis Ltd has for years studied the effects of dosing either the vitamin and/or the metabolite. Our support of this study of Calcifediol in the context of COVID-19 was motivated by the fact that the blood level of the metabolite can be increased more rapidly and more distinctly, if supplemented directly,”Said Dr. Scott Miller, Sr. Scientific Advisor at DCAL.
“There are several studies that have reported that a good vitamin D status i.e. a healthy blood level of 25-hydroxyvitamin D, can not only dramatically reduce the risk of being infected by this deadly virus but also a higher vitamin D status reduced risk for serious symptoms and death caused by the virus. This controlled study similar to the one conducted in Spain recently  demonstrates that the rapid improvement in vitamin D status can improve positive outcomes for patients infected with COVID 19,”Commented Dr. Michael Holick.
“The COVID-19 pandemic hitting the world in early 2020 resulted in unprecedented global focus of R&D efforts and of solidarity in coping with the sudden and unexpected high need for intensive care beds, which didn’t hit all countries to the same degree. It is important for us to play a role in this new challenge, not only for our corporate interests but to contribute to the possible future of the fight against COVID-19. Therefore, to follow up with this Clinical Research Study, Dishman Carbogen Amcis Ltd is currently conducting a second round of study on a larger scale in India,”Said Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd.
Patients who received the 25-hydroxy metabolite had a substantially better development of their immune protection against COVID-19 than those who received a placebo, according to the study. Dosing the metabolite raised blood levels as well as the relative percentage of lymphocytes in blood, resulting in a lower Blood Neutrophil-to-Lymphocyte Ratio.
The Active Pharmaceutical Ingredient (Calcifediol) was given by CARBOGEN AMCIS B.V. (Netherlands), and the capsules and placebo were created at the Dishman Carbogen Amcis Ltd plant in Bavla, India, specifically for this study.